Changes in the expression of plasma proteins associated with thrombosis in BRCA1 mutation carriers

Journal of Cancer Research and Clinical Oncology

Volumn 138, Issue 5, 2012, Pages 867-875

  Custodio, Ana ^a   López Farré, Antonio J ^a   Zamorano León, José J ^a   Mateos Cáceres, Petra J ^a   MacAya, Carlos ^a   Caldés, Trinidad ^a   De La Hoya, Miguel ^a   Olivera, Elena ^a   Puente, Javier ^a   Díaz Rubio, Eduardo ^a   Pérez Segura, Pedro ^a  

^a HOSPITAL CLÍNICO SAN CARLOS   (Spain)

Author keywords

BRCA1 gene; Breast cancer; Proteomics; Thrombosis

Indexed keywords

ALPHA 1 ANTITRYPSIN; ALPHA 1 ANTITRYPSIN ISOTYPE 2; ALPHA 1 ANTITRYPSIN ISOTYPE 3; ALPHA 1 ANTITRYPSIN ISOTYPE 4; ALPHA 1 ANTITRYPSIN ISOTYPE 5; APOLIPOPROTEIN A4; CLASSICAL COMPLEMENT PATHWAY C3 C5 CONVERTASE; CLASSICAL COMPLEMENT PATHWAY C3 C5 CONVERTASE ISOTYPE 1; CLASSICAL COMPLEMENT PATHWAY C3 C5 CONVERTASE ISOTYPE 2; CLASSICAL COMPLEMENT PATHWAY C3 C5 CONVERTASE ISOTYPE 3; CLASSICAL COMPLEMENT PATHWAY C3 C5 CONVERTASE ISOTYPE 4; CLASSICAL COMPLEMENT PATHWAY C3 C5 CONVERTASE ISOTYPE 5; FIBRINOGEN; FIBRINOGEN GAMMA CHAIN ISOTYPE 2; FIBRINOGEN GAMMA CHAIN ISOTYPE 3; PLASMA PROTEIN; SEROTRANSFERRIN ISOTYPE 4; TRANSFERRIN; UNCLASSIFIED DRUG; VITAMIN D BINDING PROTEIN; VITAMIN D BINDING PROTEIN ISOTYPE 1; VITAMIN D BINDING PROTEIN ISOTYPE 2; PROTEOME;

ADULT; ARTICLE; BLOOD CLOTTING DISORDER; BREAST CANCER; CLINICAL ARTICLE; CONTROLLED STUDY; DISEASE ASSOCIATION; FAMILY HISTORY; FEMALE; GENE MUTATION; HUMAN; MASS SPECTROMETRY; ONCOGENE; OVARY CANCER; PRIORITY JOURNAL; PROTEIN ANALYSIS; PROTEIN BLOOD LEVEL; PROTEIN EXPRESSION; PROTEOMICS; THROMBOSIS; TWO DIMENSIONAL ELECTROPHORESIS; BLOOD; BLOOD CLOTTING; BREAST TUMOR; CARCINOMA; CASE CONTROL STUDY; GENE EXPRESSION REGULATION; GENETICS; HETEROZYGOTE; METABOLISM; MIDDLE AGED; MUTATION; NUCLEOTIDE SEQUENCE; PATHOLOGY; PHYSIOLOGY; TUMOR SUPPRESSOR GENE;

ADULT; BLOOD COAGULATION; BLOOD PROTEINS; BREAST NEOPLASMS; CARCINOMA; CASE-CONTROL STUDIES; DNA MUTATIONAL ANALYSIS; FEMALE; GENE EXPRESSION REGULATION, NEOPLASTIC; GENES, BRCA1; HETEROZYGOTE; HUMANS; MIDDLE AGED; MUTATION; PROTEOME; THROMBOSIS;

EID: 84862286921     PISSN: 01715216     EISSN: 14321335     Source Type: Journal    
DOI: 10.1007/s00432-012-1161-y     Document Type: Article

References (58)

1. Alonso-Orgaz S, Moreno L, Macaya C, Rico L, Mateos-Cáceres PJ, Sacristán D, Pérez-Vizcaíno F, Segura A, Tamargo J, López-Farré A (2006) Proteomic study of plasma from moderate hypercholesterolemic patients. J Proteome Res 5:2301-2308. doi:10.1021/ pr060159w (Pubitemid 44330823)
2. Berstein LM, Koskela A, Boyarkina MP, Adlercreutz H (2010) Excretion of estrogens, catecholestrogens and phytoestrogens in carriers of BRCA1 gene mutations: effects of metformin. Neoplasma 57:333-338. doi:10.4149/neo-2010-04- 333
3. Bick RL (2003) Cancer-associated thrombosis. N Engl J Med 349:109-111 (Pubitemid 36818779)
4. Bombeli T, Schwartz BR, Harlan JM (1998) Adhesion of activated platelets to endothelial cells: evidence for a GPIIbIIIa-dependent bridging mechanism and novel roles for endothelial intercellular adhesion molecule 1 (ICAM-1), alphavbeta3 integrin, and GPIbalpha. J Exp Med 187:329-339. doi:10.1084/jem.187. 3.329 (Pubitemid 28080062)
5. Bourdeanu L, Luu T (2010) Arterial thrombosis associated with adjuvant chemotherapy for breast cancer: a case report. J Am Acad Nurse Pract 22:140-143. doi:10.1111/j.1745-7599.2009.00486.x
6. Brody LC, Biesecker BB (1998) Breast cancer susceptibility genes. BRCA1 and BRCA2. Medicine (Baltimore) 77:208-226 (Pubitemid 28290021)
7. Bucurenci N, Blake DR, Chidwick K, Winyard PG (1992) Inhibition of neutrophil superoxide production by human plasma a1-antitrypsin. FEBS Lett 300:321. doi:10.1016/0014-5793(92)80156-B
8. Buller HR, van Doormaal FF, van Sluis GL, Kamphuisen PW (2007) Cancer and thrombosis: from molecular mechanisms to clinical presentations. J Thromb Haemost 1(Suppl):246-254. doi:10.1111/ j.1538-7836.2007.02497.x (Pubitemid 46958840)
9. Chen S, Parmigiani G (2007) Meta-analyisis of BRCA1 and BRCA2 penetrance. J Clin Oncol 25:1329-1333. doi:10.1200/JCO.2006. 09.1066
10. de la Hoya M, Pérez-Segura P, Van Orsouw N, Díaz-Rubio E, Caldés T (2001) Spanish family study on hereditary breast and/or ovarian cancer: analysis of the BRCA1 gene. Int J Cancer 91:137-140. doi:10.1002/10970215(20010101)91:13.0. CO;2-R
11. de la Hoya M, Osorio A, Godino J, Sulleiro S, Tosar A, Perez-Segura P, Fernandez C, Rodríguez R, Díaz-Rubio E, Benítez J, Devilee P, Caldés T (2002) Association between BRCA1 and BRCA2 mutations and cancer phenotype in Spanish breast/ovarian cancer families: implications for genetic testing. Int J Cancer 97:466-471. doi:10.1002/ijc.1627 (Pubitemid 34027805)
12. Defeo K, Hayes C, Chernick M, Van Ryn J, Gilmour SK (2010) Use of dabigatran etexilate to reduce breast cancer progression. Cancer Biol Ther. doi:10.4161/cbt.10.10.13236
13. Deng CX (2006) BRCA1: cell cycle checkpoint, genetic instability, DNA damage response and cancer evolution. Nucleic Acids Res 34:1416-1426. doi:10.1093/nar/gkl010
14. Dieplinger H, Ankerst DP, Burges A, Lenhard M, Lingenhel A, Fineder L, Buchner H, Stieber P (2009) Afamin and apolipoprotein A-IV: novel protein markers for ovarian cancer. Cancer Epidemiol Biomarkers Prev 18:1127-1133. doi:10.1158/1055-9965.EPI-08- 0653
15. Ford D, Easton DF, Peto J (1995) Estimates of the gene frequency of BRCA1 and its contribution to breast and ovarian cancer incidence. Am J Hum Genet 57:1457
16. Gailani D, Renné T (2007) Intrinsic pathway of coagulation and arterial thrombosis. Arterioscler Thromb Vasc Biol 27:2507-2513 (Pubitemid 350158899)
17. Gast MC, Schellens JH, Beijnen JH (2009) Clinical proteomics in breast cancer: a review. Breast Cancer Res Treat 116:17-29. doi:10.1007/s10549-008- 0263-3
18. Guo Q, Zhang B, Dong X, Wu Y (2009) Elevated levels of plasma Wbrinogen in patients with pancreatic cancer: possible role of a distant metastasis predictor. Pancreas 38:75-79. doi:10.1097/ MPA.0b013e3181987d86
19. Haddad TC, Greeno EW (2006) Chemotherapy-induced thrombosis. Thromb Res 118:555-568 (Pubitemid 44414957)
20. Haiman M, Salvenmoser W, Scheiber K, Lingenhel A, Rudolph C, Schmitz G, Kronenberg F, Dieplinger H (2005) Immunohistochemical localization of apolipoprotein A-IV in human kidney tissue. Kidney Int 68:1130-1136. doi:10.1111/j.1523-1755. 2005.00519.x (Pubitemid 43246429)
21. Hall JM, Lee MK, Newman B, Morrow JE, Anderson LA, Huey B, King MC (1990) Linkage of early-onset familial breast cancer to chromosome 17q21. Science 250:1684-1689 (Pubitemid 120031871)
22. Hlavaty JJ, Partin AW, Shue MJ, Mangold LA, Derby J, Javier T, Kelley S, Stieg A, Briggman JV, Hass GM, Wu YJ (2003) Identification and preliminary clinical evaluation of a 50.8-kDa serum marker for prostate cancer. Urology 61:1261-1265. doi:10.1016/ S0090-4295(03)00036-0 (Pubitemid 36694030)
23. Jones JM, McGonigle NC, McAnespie M, Cran GW, Graham AN (2006) Plasma Wbrinogen and serum C-reactive protein are associated with non-small cell lung cancer. Lung Cancer 53:97-101. doi:10.1016/j.lungcan.2006.03.012 (Pubitemid 43831357)
24. Kennedy RD, Quinn JE, Johnston PG, Harkin DP (2002) BRCA1: mechanisms of inactivation and implications for management of patients. Lancet 360:1007-1014. doi:10.1016/S0140-6736(02) 11087-7 (Pubitemid 35284115)
25. Kinoshita T (1991) Biology of complement: the overture. Immunol Today 12:291-295
26. Koomen JM, Shih LN, Coombes KR, Li D, Xiao LC, Fidler IJ, Abbruzzese JL, Kobayashi R (2005) Plasma protein profiling for diagnosis of pancreatic cancer reveals the presence of host response proteins. Clin Cancer Res 11:1110-1118 (Pubitemid 40175760)
27. Kumar K, Thangaraju M, Sachdanandam P (1991) Changes observed in antioxidant system in the blood of postmenopausal women with breast cancer. Biochem Int 25:371-380
28. Li J, Zhang Z, Rosenzweig J, Wang YY, Chan DW (2002) Proteomics and bioinformatics approaches for identification of serum biomarkers to detect breast cancer. Clin Chem 48:1296-1304 (Pubitemid 34809839)
29. Li J, Orlandi R, White CN, Rosenzweig J, Zhao J, Seregni E, Morelli D, Yu Y, Meng XY, Zhang Z, Davidson NE, Fung ET, Chan DW (2005) Independent validation of candidate breast cancer serum biomarkers identified by mass spectrometry. Clin Chem 51:2229-2235 (Pubitemid 41692564)
30. López-Farré A, Zamorano-León JJ (2010) The contribution of proteomics to cancer diagnosis. Cancer Chemother 5:167-176
31. López-Farré AJ, Mateos-Cáceres PJ, Sacristán D, Azcona L, Bernardo E, de Prada TP, Alonso-Orgaz S, Fernández-Arquero M, Fernández- Ortiz A, Macaya C (2007) Relationship between vitamin D binding protein and aspirin resistance in coronary ischemic patients: a proteomic study. J Proteome Res 6:2481-2487. doi:10.1021/pr060600i (Pubitemid 47122344)
32. Mannucci PM (1995). Recent progress in the pathophysiology of Wbrinogen. Eur Heart J 16(Suppl A):25-30. doi:10.1093/eurheartj/ 16.suppl-A.25
33. Mateos-Cáceres PJ, García-Méndez A, López Farré A, Macaya C, Núñez A, Gómez J, Alonso-Orgaz S, Carrasco C, Burgos ME, de Andrés R, Granizo JJ, Farré J, Rico LA (2004) Proteomic analysis of plasma from patients during an acute coronary syndrome. J Am Coll Cardiol 44:1578-1583. doi:10.1016/j.jacc.2004.06.073 (Pubitemid 39369788)
34. Mateos-Cáceres PJ, Macaya C, Azcona L, Modrego J, Mahillo E, Bernardo E, Fernandez-Ortiz A, López-Farré AJ (2010) Different expression of proteins in platelets from aspirin-resistant and aspirin- sensitive patients. Thromb Haemost 103:160-170. doi:10.1160/ TH09-05-0290
35. McEachron TA, Pawlinski R, Richards KL, Church FC, Mackman N (2010) Protease-activated receptors mediate cross-talk between coagulation and Wbrinolysis. Blood 116:5037-5044. doi:10.1182/ blood-2010-06-293126
36. Mego M, De Giorgi U, Broglio K, Dawood S, Valero V, Andreopoulou E, Handy B, Reuben JM, Cristofanilli M (2009) Circulating tumour cells are associated with increased risk of venous thromboembolism in metastatic breast cancer patients. Br J Cancer 101:1813-1816. doi:10.1038/sj.bjc.6605413
37. Miki Y, Swensen J, Shattuck-Eidens D, Futreal PA, Harshman K, Tavtigian S, Liu Q, Cochran CL, Bennett M, Ding W, Bell R, Rosenthal J, Hussey C, Tran T, McClure M, Frye C, Hattier T, Phelps R, Haugen-Strano A, Katcher H, Yakumo K, Gholami Z, Shaffer D, Stone S, Bayer S, Wray C, Bogden R, Dayananth P, Ward J, Tonin P, Narod S, Bristow PK, Norris FH, Helvering L, Morrison P, Rosteck P, Lai M, Barrett JC, Lewis C, Neuhausen S, Cannon- Albright L, Goldgar D, Wiseman R, Kamb A, Skolnick MH (1994) A strong candidate for the breast and ovarian cancer susceptibility gene BRCA1. Science 266:66-71 (Pubitemid 24345325)
38. Miller VM, Jayachandran M, Heit JA, Owen WG (2006) Estrogen therapy and thrombotic risk. Pharmacol Ther 111:792-807 (Pubitemid 44118435)
39. Modrego J, Maroto L, Tamargo J, Azcona L, Mateos-Cáceres P, Segura A, Moreno-Herrero R, Pérez-Castellanos N, Delpón E, Pérez- Villacastín J, Rodríguez E, Macaya C, López-Farré AJ (2010) Comparative expression of proteins in left and right atrial appendages from patients with mitral valve disease at sinus rhythm and atrial Wbrillation. J Cardiovasc Electrophysiol 21:859-868. doi:10.1111/j.1540-8167.2010.01718.x
40. Nagulu M, Uday KV, Nalini K, Dharak R, Narsimha RY, Rama KD (2009) Oxidative stress and anti-oxidant status in breast cancer patients. J Pharm Res 2:62-65
41. Nand S (1993) Homeostasis and cancer. Cancer J 6:54-58
42. Osborne CK (1998) Tamoxifen in the treatment of breast cancer. N Engl J Med 339:1609-1618 (Pubitemid 28536137)
43. Ostos MA, Conconi M, Vergnes L, Baroukh N, Ribalta J, Girona J, Caillaud JM, Ochoa A, Zakin MM (2001) Antioxidative and antiatherosclerotic effects of human apolipoprotein A-IV in apolipoprotein E-deficient mice. Arterioscler Thromb Vasc Bio 21:1023-1028. doi:10.1161/01.ATV.21.6.1023 (Pubitemid 34168663)
44. Polterauer S, Grimm C, Seebacher V, Concin N, Marth C, Tomovski C, Husslein H, Leipold H, Hefler-Frischmuth K, Tempfer C, Reinthaller A, Hefler L (2009) Plasma Wbrinogen levels and prognosis in patients with ovarian cancer: a multicenter study. Oncologist 14:979-985. doi:10.1634/theoncologist.2009-0079
45. Punnonen K, Ahotupa M, Asaishi K, Hyöty M, Kudo R, Punnonen R (1994) Antioxidant enzyme activities and oxidative stress in human breast cancer. J Cancer Res Clin Onco 120:374-377. doi:10.1007/BF01247464 (Pubitemid 24101438)
46. Qin X, Swertfeger DK, Zheng S, Hui DY, Tso P (1998) Apolipoprotein AIV: a potent endogenous inhibitor of lipid oxidation. Am J Physiol 274:H1836-H1840
47. Rickles FR, Edwards RL (1983) Activation of blood coagulation in cancer: Trousseau's syndrome revisited. Blood 62:14-31 (Pubitemid 13070586)
48. Rosenberg RD, Aird WC (1999) Vascular-bed-specific hemostasis and hypercoagulable states. N Engl J Med 340:1555-1564
49. Sahni A, Simpson-Haidaris PJ, Sahni SK, Vaday GG, Francis CW (2008) Fibrinogen synthesized by cancer cells augments the proliferative effect of Wbroblast growth factor2 (FGF-2). J Thromb Haemost 6:174-175. doi:10.1111/j.1538-7836.2007.02808.x
50. Saphner T, Tormey DC, Gray R (1991) Venous and arterial thrombosis in patients who received adjuvant therapy for breast cancer. J Clin Oncol 9:286-294
51. Talmud PJ, Martin S, Steiner G, Flavell DM, Whitehouse DB, Nagl S, Jackson R, Taskinen MR, Frick MH, Nieminen MS, Kesäniemi YA, Pasternack A, Humphries SE, Syvänne M (2003) Diabetes Atherosclerosis Intervention Study Investigators. Progression of atherosclerosis is associated with variation in the alpha1-antitrypsin gene. Arterioscler Thromb Vasc Biol 23:644-649. doi:10.1161/ 01.ATV.0000065196.61663.8D (Pubitemid 36438078)
52. Tesselaar ME, Ouwerkerk J, Nooy MA, Rosendaal FR, Osanto S (2004) Risk factors for catheter-related thrombosis in cancer patients. Eur J Cancer 40:2253-2259. doi:10.1016/j.ejca.2004.06.023 (Pubitemid 39348875)
53. Tonin P, Weber B, OYt K, Couch F, Rebbeck TR, Neuhausen S, Godwin AK, Daly M, Wagner-Costalos J, Berman D, Grana G, Fox E, Kane MF, Kolodner RD, Krainer M, Haber DA, Struewing JP, Warner E, Rosen B, Lerman C, Peshkin B, Norton L, Serova O, Foulkes WD, Lynch HT, Lenoir GM, Narod SA, Garber JE (1996) Frequency of recurrent BRCA1 and BRCA2 mutations in Ashkenazi Jewish breast cancer families. Nat Med 2:1179-1183 (Pubitemid 26375392)
54. Trenz K, Lugowski S, Jahrsdörfer U, Jainta S, Vogel W, Speit G (2003) Enhanced sensitivity of peripheral blood lymphocytes from women carrying a BRCA1 mutation towards the mutagenic effects of various cytostatics. Mutat Res 544:279-288. doi:10.1016/j.mrrev.2003.06.011 (Pubitemid 37487669)
55. Vasconcellos CA, Lind SE (1993) Coordinated inhibition of actininduced platelet aggregation by plasma gelsolin and vitamin D-binding protein. Blood 82:3648-3657 (Pubitemid 24006046)
56. Villanueva J, Shaffer DR, Philip J, Chaparro CA, Erdjument-Bromage H, Olshen AB, Fleisher M, Lilja H, Brogi E, Boyd J, Sanchez-Carbayo M, Holland EC, Cordon-Cardo C, Scher HI, Tempst P (2006) Differential exoprotease activities confer tumor-specific serum peptidome patterns. J Clin Invest 116:271-284. doi:10.1172/JCI26022 (Pubitemid 43121812)
57. Zamorano-León JJ, Modrego J, Mateos-Cáceres PJ, Macaya C, Martín-Fernández B, Miana M, de las Heras N, Cachofeiro V, Lahera V, López-Farré AJ (2010) A proteomic approach to determine changes in proteins involved in the myocardial metabolism in left ventricles of spontaneously hypertensive rats. Cell Physiol Biochem 25:347-358
58. Zielinski CC, Budinsky AC, Wagner TM, Wolfram RM, Köstler WJ, Kubista M, Brodowicz T, Kubista E, Wiltschke C (2003) Defect of tumour necrosis factor-alpha (TNF-alpha) production and TNF-alpha-induced ICAM-1-expression in BRCA1 mutations carriers. Breast Cancer Res Treat 81:99-105 (Pubitemid 37211127)